ERBB2 and breast carcinoma: The combination of the two can play a role in antibody-dependent cell-mediated cytotoxicity (ADCC), which can better mediate immune cells to kill cancer cells [31].The use of NACT has improved the prognosis of HER2-positive breast cancer patients, but some HER2-positive patients still fail to achieve pCR, and considering the side effects of NACT, such as gastrointestinal side effects and cardiotoxicity.